http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#Head http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#assertion http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#provenance http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#pubinfo http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#assertion http://purl.obolibrary.org/obo/DOID_10933 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10933 http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00176 http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association http://www.w3.org/2000/01/rdf-schema#label fluvoxamine maleate extended release capsules are a selective serotonin reuptake inhibitor ssri indicated for the treatment of obsessive compulsive disorder ocd 1 one 12 week study with fluvoxamine maleate extended release capsules in adults 14 1 two 1 week studies with immediate release ir fluvoxamine tablets in adults and one 1 week study with ir fluvoxamine tablets in children and adolescents 14 1 14 3 one maintenance study with ir fluvoxamine tablets 14 2 fluvoxamine maleate extended release capsules are indicated for the treatment of obsessive compulsive disorder ocd as defined in the dsm iv obsessive compulsive disorder is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are ego dystonic and or repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable the obsessions or compulsions cause marked distress are time consuming or significantly interfere with social or occupational functioning the efficacy of fluvoxamine maleate extended release capsules was demonstrated in one 12 week trial in adults with fluvoxamine maleate extended release capsules as well as in two 1 week trials in adults and in one 1 week trial in children and adolescents ages 8 to 17 years with immediate release fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsm iv or dsm iii r see clinical studies 14 1 14 3 the efficacy of fluvoxamine for long term use was established in one maintenance study in adults with immediate release fluvoxamine tablets see clinical studies 14 2 see dosage and administration 2 4 http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00176 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#provenance http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#pubinfo http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig http://purl.org/nanopub/x/hasSignature daAZGH0ECZQNgAa8GNevtKAjSlmOXgmBCSE16gOjkpKlcJc0rFT6m6T0Bd0dfvC0XAlLfS24R8a+SWB2/ksB0tP+jABwWpIGBje0nd5bqh7ePRmLHVmC37Jrf7+MraC8xOwQwODcG3pX6I41fdb4X1kpgMzjzLIdi8vN3sIgOrc= http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://purl.org/dc/terms/created 2021-06-14T09:03:15.697+02:00 http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RABVf10a-1oi_QOfpxbSvxzQrmP7H2Tq6s7vZivqQ0x5o https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs